

FOR IMMEDIATE RELEASE

December 14, 2012

Eisai Co., Ltd.
University College London

**EISAI AND UCL FORM MAJOR DRUG DISCOVERY ALLIANCE TO DEVELOP
NEW THERAPEUTICS FOR NEUROLOGICAL DISEASES**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and University College London (UCL) announced today that they have entered into a new agreement to establish a major drug discovery and development collaboration. The unique alliance will involve researchers from both organizations working together to investigate innovative new ways of treating neurological diseases such as Alzheimer's, Parkinson's and other related disorders. The goal of the collaboration will be to identify and validate novel drug targets, develop new therapeutics and evaluate them in proof-of-concept clinical trials.

This will be the first time that joint research is conducted by a partnership involving a public institution in the United Kingdom and a pharmaceutical company. UCL and Eisai will form a Therapeutic Innovation Group (TIG) that will comprise experienced scientists from both UCL and Eisai, with the principal function of facilitating and coordinating the discovery and assessment of emerging therapeutic targets involved in neurological diseases. The TIG will also be responsible for the co-development of

potential to lead to step changes in the treatment of diseases that affect the nervous system, such as Alzheimer's. It will already build on many years of close working and collaboration with Eisai, which I am confident will lead to the development of much-needed, new effective therapeutic agents."

Commenting on the partnership, Professor Stephen Caddick, Vice-Provost (Enterprise) at UCL, added, "UCL is committed to working with partners who have a shared vision to translate research findings into products that will have a tangible, positive impact on society. This strategic alliance between UCL and Eisai combines research excellence, clinical insight and commercial expertise, which will undoubtedly improve prospects for development of new treatments for patient benefits."

[Please refer to the following note for further information on University College London.]

Media Inquiries	
Public Relations Department Eisai Co., Ltd. TEL: +81-3-3817-5120	Media Relations (UCL Enterprise) University College London TEL: +44 (0) 207 679 9063

<Note to editors>

1. About University College London

Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and m